Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 5:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 400 matching trials from the live ClinicalTrials.gov search.
Filters: "early Alzheimer" Clear all
Completed No phase listed Observational

Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) Study

NCT02420756
View directory record Official record
Conditions
Alzheimer's Disease, Dementia, Mild Cognitive Impairment
Interventions
PET Scan
Device
Lead sponsor
American College of Radiology
Other
Eligibility
65 Years and older
Enrollment
18,488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Oct 8, 2026, 5:40 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)

NCT03114657
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Crenezumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 85 Years
Enrollment
806 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
48
States / cities
Scottsdale, Arizona • Fayetteville, Arkansas • Little Rock, Arkansas + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2020 · Synced Oct 8, 2026, 5:40 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Family Caregiver Online Survey (Dementia and Swallowing Difficulties)

NCT06471660
View directory record Official record
Conditions
Dementia, Dysphagia, Dementia Alzheimers, Dementia, Vascular, Dementia, Mixed, Dementia With Lewy Bodies, Dementia Frontal, Dementia, Mild, Dementia Moderate, Dementia Severe, Parkinson Disease Dementia, Dementia Frontotemporal
Interventions
Not listed
Lead sponsor
University of Oregon
Other
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 8, 2026, 5:40 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Metformin in Alzheimer's Dementia Prevention

NCT04098666
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Placebo oral tablet, extended release metformin
Drug
Lead sponsor
Columbia University
Other
Eligibility
55 Years to 90 Years
Enrollment
326 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
22
States / cities
Irvine, California • Palo Alto, California • Washington D.C., District of Columbia + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 8, 2026, 5:40 PM EDT
Not yet recruiting Phase 1 Interventional

Repurposing a Combination Antiretroviral Drug Therapy to Target Retrotransposons and Treat Early Alzheimer's Disease

NCT07795307
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Emtricitabine and tenofovir disoproxil fumarate combination, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
55 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 8, 2026, 5:40 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)

NCT01626378
View directory record Official record
Conditions
Behavioral Variant Frontotemporal Dementia (bvFTD)
Interventions
TRx0237, Placebo
Drug
Lead sponsor
TauRx Therapeutics Ltd
Industry
Eligibility
Up to 79 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
24
States / cities
Los Angeles, California • Newport Beach, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Oct 8, 2026, 5:40 PM EDT
Recruiting No phase listed Observational

NYSCF Scientific Discovery Biobank

NCT06203106
View directory record Official record
Conditions
ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Batten Disease, Corticobasal Degeneration, Dementia, Frontotemporal Dementia, Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson Disease, Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy, INAD, Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Macular Degeneration, Ovarian Cancer, Cervical Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer, PTSD, Post Traumatic Stress Disorder
Interventions
Biological Sample Collection
Other
Lead sponsor
New York Stem Cell Foundation Research Institute
Other
Eligibility
30 Days and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2045
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Oct 8, 2026, 5:40 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases

NCT02649985
View directory record Official record
Conditions
Multiple Sclerosis, Alzheimer's Disease
Interventions
[F-18]PBR06, [C-11]PBR28
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 8, 2026, 5:40 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease

NCT03289143
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Semorinemab, Placebo, [18F]GTP1
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
43
States / cities
Birmingham, Alabama • Glendale, California • Irvine, California + 39 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Oct 8, 2026, 5:40 PM EDT
Not listed No phase listed Observational

Chromatic Pupillometry to Assess the Melanopsin-Light Pathway in Progressive Supranuclear Palsy

NCT03330353
View directory record Official record
Conditions
PSP - Progressive Supranuclear Palsy, PD - Parkinson's Disease, AD - Alzheimer's Disease, ALS (Amyotrophic Lateral Sclerosis)
Interventions
Pupillometry
Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
55 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Oct 8, 2026, 5:40 PM EDT
Completed Phase 4 Interventional

Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Dementia

NCT04522739
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease
Interventions
Spironolactone, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
50 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 8, 2026, 5:40 PM EDT
Recruiting Not applicable Interventional

Music for Pain and Dementia

NCT07602283
View directory record Official record
Conditions
Alzheimer Disease, Dementia, Mild Cognitive Impairment, Peer-bonded Caregiver, Caregiver
Interventions
Drumming session, Music-listening session
Behavioral
Lead sponsor
Yale University
Other
Eligibility
50 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 8, 2026, 5:40 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Participants With Early Alzheimer's Disease After Multiple Dose Administration

NCT07780383
View directory record Official record
Conditions
Alzheimer's Disease, Healthy Participants
Interventions
BMS-986446
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 80 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
6
States / cities
Anaheim, California • Bradenton, Florida • Daytona Beach, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 8, 2026, 5:40 PM EDT
Active, not recruiting No phase listed Observational

Illuminating Neuropsychological Dysfunction and Systemic Inflammatory Mechanisms Gleaned After Hospitalization in Trauma-ICU Study

NCT03098459
View directory record Official record
Conditions
Delirium, Cognitive Impairment, Alzheimer; Early Onset, Trauma, Polytrauma, Traumatic Brain Injury, ICU, Critical Illness
Interventions
Non-interventional observational prospective cohort study
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 8, 2026, 5:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sound Estimation and Accuracy Task

NCT02271685
View directory record Official record
Conditions
Parkinson's, Alzheimer Disease
Interventions
Instructions about Overestimates, Instructions about Parkinson's, Instructions about Underestimates, Instructions about Alzheimers
Other
Lead sponsor
Carnegie Mellon University
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 21, 2015 · Synced Oct 8, 2026, 5:40 PM EDT
Completed Phase 2 Interventional Results available

Tetra PICASSO AD Trial: Study to Evaluate Effects of BPN14770 in Early Alzheimer's Subjects

NCT03817684
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
BPN14770, Placebo
Drug
Lead sponsor
Tetra Discovery Partners
Industry
Eligibility
55 Years to 85 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
41
States / cities
Gilbert, Arizona • Bellflower, California • Costa Mesa, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Oct 8, 2026, 5:40 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Can (Optical Coherence Tomography) Pictures of the Retina Detect Alzheimer's Disease at Its Earliest Stages?

NCT06023446
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
Optical Coherence Tomography
Diagnostic Test
Lead sponsor
University of California, Davis
Other
Eligibility
50 Years to 89 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Oct 8, 2026, 5:40 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Davos Alzheimer's Collaborative Study: Sequential Administration of Digital Testing To Screen For Cognitive Impairment Followed By Blood Based Biomarkers To Assist With Timely Detection And Accurate Diagnosis Of Alzheimer's Disease

NCT05379348
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Cognitive Assessment
Other
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
65 Years and older
Enrollment
1,423 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 8, 2026, 5:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Normative Values for Cognitive Testing and Alzheimer's Imaging Biomarkers in Young Adults

NCT01609335
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
F-18 FDG, C-11 PiB
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years to 49 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 8, 2014 · Synced Oct 8, 2026, 5:40 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Establishment of a Bank of Biospecimens for Future Research on Age-related Cognitive Disorders

NCT00911690
View directory record Official record
Conditions
Dementia, Alzheimers Disease
Interventions
Not listed
Lead sponsor
Corewell Health East
Other
Eligibility
60 Years to 90 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 4, 2016 · Synced Oct 8, 2026, 5:40 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia

NCT05374278
View directory record Official record
Conditions
Alzheimer Disease, Frontotemporal Dementia, Dementia
Interventions
[18F]RP-115 PET/MRI or PET/CT and MRI
Drug
Lead sponsor
David Wilson
Other
Eligibility
40 Years to 75 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Oct 8, 2026, 5:40 PM EDT
Terminated Phase 2 Interventional Results available

Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil

NCT01712074
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
PF-05212377 (SAM-760), Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
60 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
40
States / cities
Costa Mesa, California • Imperial, California • Rancho Mirage, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Oct 8, 2026, 5:40 PM EDT
Terminated Phase 3 Interventional

Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects

NCT06304883
View directory record Official record
Conditions
Early Alzheimer's Disease
Interventions
Experimental: ALZ-801
Drug
Lead sponsor
Alzheon Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
29
States / cities
Phoenix, Arizona • Sun City, Arizona • Costa Mesa, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 8, 2026, 5:40 PM EDT
Terminated Not applicable Interventional

Alzheimer's Disease Imaging With PET/MRI - Beta-amyloid

NCT02343757
View directory record Official record
Conditions
Dementia, Alzheimer Disease
Interventions
PET/MRI
Device
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
21 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 12, 2022 · Synced Oct 8, 2026, 5:40 PM EDT